The global continuous glucose monitoring systems market reached a value of US$ 5.46 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.56 Billion by 2027, exhibiting a CAGR of 9.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Continuous glucose monitoring systems (CGMS) are technologically advanced devices that automatically track blood glucose levels. They consist of a transmitter-integrated sensor that functions through a transcutaneous or subcutaneous route to continuously measure the glucose concentration in interstitial fluid. The transmitter then sends the information to a wireless monitor that can be clipped to clothes. Continuous glucose monitoring systems assist in providing a complete profile of diabetes, alerting highs and lows of blood sugar levels, detecting patterns, and increasing patient insights regarding physical activity, medication choices, food portions and stress. As compared to conventional glucose monitoring devices, CGMS are prick-free as they can be placed over the skin, thus aiding in providing real-time information in a quick and painless fashion.
Continuous Glucose Monitoring Systems Market Trends:
The rising geriatric population across the globe that are more susceptible to developing diabetes is creating a positive outlook for the market. CGMS is commonly used for measuring glucose and insulin level in the body, which further sounds an alarm if it drops or rises to a dangerous level. In line with this, the widespread product utilization to identify hypoglycemia and hyperglycemic situations in real-time is favoring the market growth. Moreover, significant improvements and new technological advancements in CGMS that aid in detecting glycated hemoglobin (Hb1ac) in patients with diabetes are providing a considerable boost to the market growth. Additionally, the integration of artificial pancreas device systems with CGMS technology to pump insulin and administer optimum dosage to manage the blood sugar levels of patients is positively impacting the market growth. Apart from this, the introduction of non-invasive CGMS devices as a convenient alternative, extensive research and development (R&D) activities and the increasing demand for less or minimally invasive diagnostic tools are anticipated to drive the market further toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global continuous glucose monitoring systems market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on component, demographics and end user.

Breakup by Component:
Sensors
Transmitters and Receivers
Integrated Insulin Pumps

Breakup by Demographics:

Child Population (?14 years)
Adult Population (>14 years)

Breakup by End User:

Clinics and Diagnostics Centers
ICUs
Home Healthcare

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc. and Waveform Technologies Inc.

Key questions answered in this report:
How has the global continuous glucose monitoring systems market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global continuous glucose monitoring systems market?
What are the key regional markets?
What is the breakup of the market based on the component?
What is the breakup of the market based on the demographics?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global continuous glucose monitoring systems market and who are the key players?
What is the degree of competition in the industry?